Size:100ug
Purification:Immunogen affinity purified
Form:liquid
Purity:?95% as determined by SDS-PAGE
Host:Rabbit
Clonality:polyclonal
Clone ID:
Isotype:IgG
Storage:PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20? for 12 months(Avoid repeated freeze / thaw cycles.)
Background:GTPase activator for the Rho-type GTPases.
Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens(mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease(GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation(BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte(CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
Immunogen:histocompatibility(minor) HA-1
Synonyms:KIAA0223
Observed MW:140-150kd
Uniprot ID:Q92619
Reactivity:Human, Mouse, Rat
Tested Application:ELISA, WB, IHC
Recommended dilution:WB: 1:500-1:2000; IHC: 1:20-1:200
Gene ID:23526
Research Area:Signal Transduction